Skip to main content

Palantir jumps 17% on report of $44 million FDA contract

The deal is worth $44.4 million and will focus on powering drug reviews and inspections, according to the report.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.